What is after cytokine-blocking therapy, a novel therapeutic target — Synovial Epstein-Barr virus for rheumatoid arthritis
| Autor: | Masami Takei, Takamasa Nozaki, Hidetaka Shiraiwa, H. Inomata, Shigemasa Sawada |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Immune defense
Epstein-Barr Virus Infections Herpesvirus 4 Human medicine.medical_treatment Immunology Retinoic acid Tretinoin medicine.disease_cause Antiviral Agents Virus Proinflammatory cytokine Arthritis Rheumatoid chemistry.chemical_compound medicine Humans Immunology and Allergy business.industry Synovial Membrane medicine.disease Epstein–Barr virus Cytokine chemistry Synovial Cell Rheumatoid arthritis Cytokines business |
| Zdroj: | Autoimmunity Reviews. 6:126-130 |
| ISSN: | 1568-9972 |
| DOI: | 10.1016/j.autrev.2006.08.014 |
| Popis: | There has been significant progress in cytokine-blocking therapy for treatment of rheumatoid arthritis (RA) However, inhibition of cytokines involved in immune defense raises severe side effects. The cost of cytokine-blocking treatment is another major issue. Why are levels of inflammatory cytokines increased in RA patients? We have a large amount of circumstantial and direct evidence for the presence of Epstein-Barr virus (EBV) in RA synovial cells. Here, we provide an overview of the implications for novel approaches to therapy for RA patients, based on the most recent available evidences of anti-viral agents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect